糠酸莫米松0.1%降低乳腺癌乳房切除术后放疗患者重度急性放射性皮炎的随机试验
一项双盲随机试验纳入124例接受胸壁±淋巴结放疗(50 Gy)的乳腺癌术后患者,比较糠酸莫米松0.1%(MF)与Eucerin Original(E)乳膏预防中重度急性放射性皮炎的效果。MF组湿性脱屑发生率为43.8%,显著低于E组的66.7%(P=.012),且最大皮肤毒性发生率更低、发生3级皮炎时间更长,但患者报告的皮肤结局无差异。
要点
- MF组湿性脱屑发生率为43.8%,显著低于E组的66.7%(P=.012)。
- MF组最大皮肤毒性发生率更低(P=.036),发生3级皮炎时间更长(46天 vs 35.5天,P≤.001)。
- 两组患者报告的皮肤结局无差异。
核心结论
- 乳腺癌患者在乳房切除术后放疗期间使用糠酸莫米松0.1%较对照乳膏显著降低湿性脱屑发生率。
研究设计与样本
- 两臂、双盲随机试验,2013年5月至2016年2月纳入124例接受胸壁±淋巴结放疗(50 Gy)的乳腺癌患者,按1:1随机分配至糠酸莫米松0.1%组或Eucerin Original乳膏组,从放疗第1天至放疗后14天每日涂抹两次。
- 按放疗技术、体重指数和重建状态分层,所有患者均使用每日3至10 mm的bolus。
主要发现
- 全队列湿性脱屑发生率为54.8%,MF组为43.8%,E组为66.7%(P=.012)。
- MF组最大皮肤毒性发生率更低(P=.036),发生3级皮炎时间更长(46天 vs 35.5天,P≤.001)。
- 两组患者报告的皮肤结局无差异。
关键数值与推荐
- 主要终点为研究者评估的≥2级(常见不良事件评价标准第4.03版)伴湿性脱屑的急性放射性皮炎或任何≥3级皮炎。
- 次要终点为最大级别皮炎发生时间和采用Skindex-16皮肤相关生活质量问卷的患者报告皮肤症状。
- 评估在基线、放疗期间每周及放疗后2周进行。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A 2-arm, double-blinded randomized trial was conducted to evaluate the efficacy of 0.1% mometasone furoate (MF) versus Eucerin Original (E) cream in preventing the development of moderate to severe acute radiation dermatitis (ARD) in breast cancer patients receiving postmastectomy radiation (PMRT). METHODS: Breast cancer patients undergoing chest wall with or without nodal radiation therapy (RT) (50 Gy) were eligible. Randomization (1:1) was to MF or E, applied twice daily from day 1 of PMRT to 14 days after PMRT. Patients were stratified by RT technique, body mass index, and reconstruction status. Daily bolus of 3 to 10 mm was applied in all patients. The primary endpoint was the development of provider-assessed grade ≥2 (Common Terminology Criteria for Adverse Events version 4.03) ARD with moist desquamation or any grade ≥3 dermatitis. Secondary endpoints were time to occurrence of maximum-grade dermatitis and patient-reported skin symptoms using a skin-related quality of life questionnaire, Skindex-16. Assessments were performed at baseline, weekly during PMRT, and 2 weeks after PMRT. RESULTS: 124 patients were enrolled between May 2013 and February 2016. Of those, 35% had pathologic stage III disease, 6% had cT4d disease, and 68% underwent reconstruction. Sixty percent received 3-dimensional conformal RT with photons only to the chest wall, 18% received electrons and photons, and 23% received inverse-planned intensity modulated RT. Groups were well balanced for age, skin type, and stage. The rate of moist desquamation was 54.8% in the entire cohort, with a significantly reduced incidence in the MF arm than in the E arm (43.8% vs 66.7%; P = .012). The MF arm had a lower incidence of maximum skin toxicities (P = .036) and longer time to development of grade 3 dermatitis (46 days vs 35.5 days, respectively; P ≤ .001). There was no difference in patient-reported skin outcomes between arms. CONCLUSIONS: Breast cancer patients receiving MF during PMRT experienced significantly reduced rates of moist desquamation in comparison with a control cream.
引用
- Ho AY, Olm-Shipman M, Zhang Z, et al. A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation. Int J Radiat Oncol Biol Phys. 2018. PMID: 29726361. doi:10.1016/j.ijrobp.2018.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。